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Abstract
Purpose: Physiologically-based pharmacokinetic (PBPK) models provide a rational mechanistic approach for
predicting the time course of macromolecules in plasma. Population PBPK models for large molecules necessitate
incorporation of lymphatic circulation to mechanistically account for biodistribution. Moreover, characterization of
subcutaneous absorption requires consideration of the microvascular transit from the injection site to the systemic
circulation. A PBPK model for a pegylated peptide conjugate, previously developed for primates, was modified to
describe the lymphatic uptake in a population of humans by incorporation of interindividual variability in the
lymphatic circulation and a unique lymphatic drainage compartment (LDC). The model was then used to simulate
the time course of the drug in a population of humans and compared to the same drug administered to a group
of human subjects participating in a first-in-human study.
Methods: Organ, blood and lymph masses for the population were sampled from either normal or log-normal
distributions. Blood flows were calculated for each organ based on mean organ perfusion per gram of organ tissue
and lymphatic flow was set as a fixed fraction of blood flow. Interindividual variability in lymphatic volume was
assumed to be similar to that of blood volume. The volume of the LDC was parameterzed as a fraction of the
injection volume. Sensitivity analysis was performed to study uncertain parameters and distribution assumptions.
Results: The population generator was capable of simulating a virtual population incorporating the lymphatic
circulation. Incorporation of a LDC resulted in similar line shape relative to the observed data and incorporation of
anthropometric variability accounted for individual differences in the absorption and elimination phases across all
dose cohorts. Line shape was sensitive to the inclusion of LDC while peak and elimination portions of the time
course were influenced by the magnitude of variance assumed for blood volume and renal clearance, respectively.
Conclusion: Lymphatic circulation can be incorporated into a population PBPK model assuming similar
interindividual variability as observed for blood volume. Incorporation of an LDC, where the volume of this transit
compartment is proportional to the SC injection volume may be an important mechanistic means of predicting the
transit from the SC depot to the systemic circulation.
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Background
The importance of the subcutaneous (SC) route to the
drug development industry is evident in the growing
number of drug products available for SC administra-
tion. In 2014, the U.S. Food & Drug Administration
approved 41 new molecular entities and biological li-
censing applications, four of which had first approvals
for subcutaneous (SC) administration (2015). The indus-
try has also witnessed conversion of intravenous (IV) to
SC routes for a number of therapies where treatment
that was previously relegated to a hospital can now
largely be addressed in an ambulatory setting (e.g. IV
heparin to SC low molecular weight heparins for treat-
ment of deep vein thrombosis). With a growing em-
phasis on SC administration as the primary route for
development, reliance on reliable pharmacokinetic (PK)
scaling methods (pre-clinical animal species to human)
is correspondingly increasing.
When designing clinical pharmacology (Phase 1) and
in particular first-in-human (FIH) studies, there is con-
siderable importance placed on predicting the peak
(Cmax) and overall exposure (AUC). This is particularly
critical when relating the exposure observed in pre-
clinical species to observed adverse events. Appreciating
the temporal relationship between dosing time and
Cmax, as well as an estimate of the drug’s plasma half-
life (T1/2), are useful for a priori design of early human
research studies to mitigate the need for protocol
amendments and reduce the burden of interim PK
assessments.
In traditional allometric theory, prediction of human
PK from animals has largely focused on estimating mean
human exposure by scaling the mean clearance value of
three or more preclinical species (Mahmood and Balian
1996; Mordenti 1986). For macromolecules, and particu-
larly for monoclonal antibodies (mAbs) exhibiting linear
PK, single-species (primates) simplified allometric tech-
niques have yielded useful predictions (Offman and
Edginton 2013; Wang and Prueksaritanont 2010; Deng,
et al. 2011; Dong, et al. 2011; Ling, et al. 2009). These
methods however, provide no information as to the time
course of a drug after administration, and have princi-
pally been employed for the IV route of administration.
Dedrick plots have been demonstrated to have some
utility in predicting the time course of IV administered
monoclonal antibodies (mAbs), but have not yet been
reported to yield similar predictive capacity for SC ad-
ministered proteins (Ling, et al. 2009).
Predicting the SC time course of a drug in a popula-
tion of humans from animal models is considerably
more complex compared to prediction for a “mean hu-
man”. For macromolecules, this is further complicated
by a lack of knowledge regarding extravascular bioavail-
ability and/or non-linearity in PK.
Whole body physiologically-based PK (WB-PBPK)
modeling provides a rational mechanistic approach for
predicting the time course of drugs in the vasculature
and potentially other tissue compartments, and has
demonstrated utility in describing the mean time course
of IV administered macromolecules in both pre-clinical
and human species (Baxter, et al. 1995; Ferl, et al. 2005;
Davda, et al. 2008; Urva, et al. 2010; Shah and Betts
2012). To extrapolate to SC administration however,
these models may require modification to better account
for local lymphatic drainage from the SC depot site.
The lymphatic system provides unidirectional trans-
port for fluid and protein by collecting constituents from
the interstitial space and returning them to the blood
(Swartz 2001). While transport is convective in nature,
movement of lymphatic fluid and macromolecules
transported into and by the lymphatics can be influ-
enced by muscle contractions and ambient temperature
(Olszewski, et al. 1977; O’Morchoe, et al. 1984; Swartz
2001). Lymphatic vessels are categorized into capillaries,
larger collecting vessels, nodes, trunks and ducts, and
likely, many capillaries drain a single injection site
(Porter, et al. 2001; Swartz 2001). Cannulation tech-
niques in animal models have allowed for the quantita-
tion of macromolecule uptake into the lymphatics, and
whilst seminal in confirming lymphatic involvement in
biodistribution and contributing to our understanding of
how macromolecule size influences uptake, they do not
address the actual local drainage dynamics from the
depot into the immediate lymphatic capillaries (Porter,
et al. 2001; Supersaxo, et al. 1990; Supersaxo, et al.
1988). Skin lymphatics include superficially spread, sub-
papillary fine mesh and deeper vessels which empty into
larger vessels draining the SC space before reaching the
collecting ducts (Lubach, et al. 1996). Mathematical
modeling lymphatic drainage remains challenging, as
there is no non-invasive method for differentiating the
volume of lymphatics attributed to local drainage at the
site of drug administration and that attributed to the re-
mainder of the lymphatic vessels.
WB-PBPK models for macromolecules and particularly
mAbs have universally incorporated a lymph node com-
partment with convective transport dragging drug across
the organ vascular-interstitial interface, into the lymph
node compartment and subsequently into venous circu-
lation (Baxter, et al. 1995; Urva, et al. 2010; Ferl, et al.
2005; Shah and Betts 2012; Davda, et al. 2008; Offman
and Edginton 2015). Although mean values for a lymph
node compartment are reported, it is unclear as to
whether the reported volumes relate to the sum of all
nodes, ducts, collectors and capillaries or to what extent
these vary among individuals. Furthermore, population
PBPK algorithms, available in the public domain, have
not reported compartment characteristics (i.e. mean,
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variance) for the lymphatic system or lymph flow, and
consequently don’t readily lend themselves to the study of
SC administration of macromolecules in a population of
individuals (McNally, et al. 2014; Willmann, et al. 2007).
Employing a WB-PBPK modeling approach, we previ-
ously characterized the SC time course of a novel pegy-
lated peptide conjugate in primates which was then
scaled to humans at three different dose levels in a FIH
single ascending dose (SAD) trial (Offman and Edginton
2015). Upon further examination across a wider range of
doses, the model predictions suggested further model re-
finement in the lymphatic uptake processes would im-
prove predictive capacity of the model, particularly in the
very early portion of the concentration vs. time profile.
To further investigate the contribution of local lymph-
atic capillary drainage from the SC space on the time
course and shape of the plasma concentration vs. time
profile (CPT), and to improve our understanding as to
which parameters influence the variability of the CPT in
a population, we endeavored to expand on our previous
work and develop a population PBPK model which in-




CPT data was obtained for a novel pegylated peptide
conjugate (approximately 45 kDa) as it transitioned from
preclinical to early clinical development. The compound
(name and target withheld for commercial proprietary
purposes), predominantly consists of a freely water sol-
uble, linear PEG-40 conjugated to a small (approxi-
mately 1 kDa) peptide portion. The current evaluation
includes concentration and anthropometric data from 20
healthy Australian male subjects, 18–55 years of age and
within a weight range of 60–80 kg who participated in a
FIH, SAD investigation. The investigation was conducted
under good clinical practice and according to the ethical
principles outlined in the Declaration of Helsinki. Each
subject received a single SC dose between 45 mg and
720 mg into the abdominal region with sequential PK
sampling post-dose until approximately 1050 h. The
concentration of the injection ranged from 100 mg/mL
to 150 mg/mL with multiple injections for some dose
levels such that the volume in any single injection would
not exceed 2 mL. Plasma was analyzed employing an LC-
MS/MS method with a limit of quantitation of 1 ug/mL.
Model structure
The base model structure has been previously described
(Offman and Edginton 2015), and was slightly modified
to better characterize the SC drainage into the lym-
phatics. Representative mass balance equations are pro-
vided for reference in Additional file 1. The proposed
overall and sub-compartment structures are based in
part on the PBPK platform developed previously by Shah
and Betts and is depicted graphically in Fig. 1a-b (Shah
and Betts 2012). The overall structure consists of a
unique compartment for each of the venous and arterial
circulation, a lymph node compartment and 15 individ-
ual organs where each organ consists of a vascular and
interstitial sub-compartment. The skin interstitial com-
partment is further sub-divided into a depot and residual
space where the SC dose inputs directly into the depot.
The SC depot volume was parameterized as being
equivalent to the total injection volume, which varied
from 0.45–4.8 mL depending on the dose level and con-
centration injected. Transport from the interstitium into
the lymphatic space is via a convective flow with a small
degree of resistance parameterized as lymph flow and a
lymphatic reflection coefficient (σi), as proposed by Garg
and Balthasar (2007). In our previously developed model
based on primates,, drug in the SC depot space emptied
directly into a lymphatic compartment (Offman and
Edginton 2015). In the current model, an intermediate
anatomical volume was added in order to include the lo-
calized lymphatic drainage from the SC depot into adja-
cent lymph vessels, which we will refer to as the
lymphatic drainage compartment (LDC). The LDC sub-
sequently drains into the greater lymphatic system com-
partment. Lymphatic flow empties from the lymph
compartment into the venous circulation and re-enters
the interstitial space in a one-way circuit via the same
lymphatic convective flow. Transfer from the organ
plasma vascular space to the interstitial space is similarly
driven by convective flow and constrained by vascular
reflection coefficients (σv) that were initially set at values
proposed by Shah and Betts (2012). However, as per the
previous model, all organ vascular reflection coefficients
are scaled by the parameter σsf, which was previously op-
timized (Offman and Edginton 2015). Fraction vascular
(Fvv) and interstitial (Fvic) were retained at the same values
as in the original model (Offman and Edginton 2015).
Virtual population development
Prior to simulation of a virtual population, the target
population for simulation needs to be defined. Since the
observed PK data was obtained in a group of Caucasian
Australian men, average height and weight and corre-
sponding coefficients of variations for these anthropo-
metric measurements in non-obese Australian males
were obtained from Craig, et al. (2001). As described by
Willmann et al., first, height values were randomly
drawn from a normal distribution for a population of
1000 male subjects followed by sampling of each organ
compartment mass for each individual in the virtual
population (Willmann, et al. 2007). To mitigate the like-
lihood of individuals with the same height being
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allocated identical organ weights, organ masses were
drawn either from a normal or log-normal distribution
(Table 1) that was re-centered to the size of the individ-
ual employing an allometric scaling factor according to
the ¾ power rule (Willmann, et al. 2007). To avoid the
selection of extreme outliers, organ mass distributions
were symmetrically truncated to the 95th percentile and,
when necessary to prevent negative masses, constrained
at the lower bound to one tenth the re-centered mean
value. A visual check was then performed to evaluate the
impact of truncation and constraining the lower bound
by repeating the simulations for all dose levels in the ob-
served data where parameters initially drawn from a
normal distribution were then drawn from a log-normal
distribution.
All model compartments, with the exception of
skin, blood and lymph were scaled according to equa-
tion (1), where the mean mass of each organ O, de-
noted MmeanO , is dependent on a single variable, in
this case the body height of the individual, Hindiv, via
an equation of the form MmeanO ¼ cHpindiv, where c is a
sex- and race-dependent constant and p is a chosen
exponent. Organ masses for a reference individual
MrefO
 
were obtained from the BioDmet database
where Href is the height of a reference individual
Fig. 1 a Structure of a whole-body PBPK platform (adapted from Shah and Betts 2012). Solid black arrows indicate plasma flow. Dark grey dashed
arrows indicate lymphatic transport. S. Int. and L. Int. represent small and large intestines. Each organ compartment includes lymphatic flow
emptying from the organ into the lymph nodes. For IV administration, drug is administered into the “Venous Supply”. For SC administration, drug
is administered into the “Skin Compartment” interstitium. b Sub-compartment model for all organs other than skin (top) and skin (bottom)
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weighing 71 kg with a body mass index of 24 kg/m2
(corresponding to a height of 172 cm) (Graf, et al.
2012). Where organ volume and or mass were to be
interconverted, density values for organs were ob-
tained from ICRP references (2002a).





Body height has been identified previously by de la
Grandmaison as a better predictor of organ size in the
majority of cases and the formula is rooted in allometric
theory (de la Grandmaison, et al. 2001). An exponent of
¾, although previously reported, was largely empiric for
the current report, and others have used a range of values,
upwards of 2, in a similar fashion (Willmann, et al. 2007;
Bosgra, et al. 2012).
Blood and lymph mass means were scaled based on
reference body weight (Wref, equation 2) as blood and
lymph vessels are assumed to increase with increasing
body weight as opposed to height.





Skin mass was scaled based on body surface area
(BSA) as per equation 3 where BSA was estimated
based on equation 4 and where the constant values
for a, b and c were as proposed by Gehan and







BSAindiv ¼ a Windivð Þb Hindivð Þc ð4Þ
The total body mass (BM) of a virtual individual was
then calculated as the sum of the bloodless organ
masses, lymph mass, skin mass and blood mass and the
BM of the final population individuals (n = 1000) in-
cluded only individuals within the range of 60–80 kg,
consistent with the observed population. As previously
suggested by Peters blood mass was partitioned as 2/3
venous and 1/3 arterial (Peters 2008).
Table 1 Anatomical and physiologic parameters with distributions used in the population PBPK model
Meana CV % Distribution CV % Source
Mean Weight 71 (kg) / / /
Compartment Mass % Body Weight / / /
Adipose 18.540 0.43 Log-normal (Heymsfield, et al. 2007)
Brain 1.968 0.10 Normal (Heymsfield, et al. 2007)
Blood (Arterial/Venous) 8.005 0.22 Log-normal (Feldschuh and Enson 1977)
Bone 13.952 0.14 Normal (Heymsfield, et al. 2007)
Heart 0.448 0.19 Normal (de la Grandmaison, et al. 2001)
Kidney 0.421 0.25 Normal (de la Grandmaison, et al. 2001)
Large Intestines 1.52 0.2 Normal (McNally, et al. 2014)
Liver 2.707 0.23 Normal (de la Grandmaison, et al. 2001)
Lung 1.569 0.36 Log-normal (de la Grandmaison, et al. 2001)
Lymph 0.359 0.22 Log-normal Empirically assumed to be similar to
circulatory system variability
Muscle 40.702 0.16 Log-normal (Heymsfield, et al. 2007)
Other Remainder not accounted
for by other organs
0.2 Normal Empirically selected
Pancreas 0.136 0.27 Normal (de la Grandmaison, et al. 2001)
Skin 4.477 0.1 Log-normal Empirically selected
Small Intestines 1.068 0.12 Normal (McNally, et al. 2014)
Spleen 0.244 0.56 Log-Normal (de la Grandmaison, et al. 2001)
Thymus 0.008 0.05 Log-Normal Empirically selected
Hematocrit 0.42 0.02 Normal (Jacob, et al. 2012)
Renal Filtration Fraction 0.20 0.0294 Normal (Ritz, et al. 1998)
Vfrac 0.25 0.68 Fitted Parameter
aMean organ mass was obtained from the BioDMET database (Graf, et al. 2012)
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For the derivation of organ-specific blood flows in
each individual, mean perfusion values were first calcu-
lated for each organ to serve as a reference value assum-
ing that perfusion rates would be constant across the
population. Organ reference perfusion values were ob-
tained by multiplying the cardiac output in a reference
71 kg male (Graf, et al. 2012) by the blood flow fraction
to that organ and then dividing the reference blood flow
by the mean organ mass. Individual organ blood flows
(QB) were then obtained by multiplying the organ
weight of the individual by the reference perfusion value.
Plasma flow (QP) was derived by multiplying QB by a
factor of 1-hematocrit (hct), where hct was assumed to
be log-normally distributed (Table 1).
Consistent with the PBPK model for a reference male,
lymph flow was set at a constant fraction of blood flow
(LO) where the previously employed value of 0.2 % was
used for all organs except skin (LS), which was set to
0.1 % (Offman and Edginton 2015). The fraction of
0.2 % corresponds to the upper range of lymph flow re-
ported by Swartz whereas 0.1 % was obtained by
optimization in the reference male model (Swartz 2001).
Clearance of the pegylated protein was previously
characterized by both renal (RCL) and non-renal clear-
ance (NRCL). RCL was set at 0.1 % of glomerular filtra-
tion rate (GFR) consistent with previously investigated
PEG-conjugated therapeutics. To allow for incorporation
of interindividual variation in GFR, the GFR was derived
from the product of renal plasma flow and filtration
fraction (FF) where FF was drawn from a log-normal dis-
tribution (Table 1) (Baumann, et al. 2014; Offman and
Edginton 2015). The acronym FGFR is used to represent
the fraction of glomerular filtration attributed to renal
clearance. To avoid the risk of including individuals with
GFRs in the impaired region of glomerular function, and
to avoid extremely large values for GFR, only individuals
with a GFR within the range of 90–150 mL/min were used
in the simulation (Delanaye, et al. 2012).
For the compound in question, NRCL was assumed to
occur by both macrophagic uptake of the non-pegylated
moeity and by non-specific cleavage of the pegylated
chain (Caliceti and Veronese 2003). NRCL was opti-
mized in primates in our previous model and for the
current model NRCL in the primate was scaled to each
simulated human based on the body weight ratio of a
simulated human individual and the mean weight of the
primate (3.4 kg) (Offman and Edginton 2015). The NRCL
was then apportioned based on the relative volume of
each compartment in which NRCL was assumed to occur.
Optimization of LDC
As the volume of drug product injected into the SC
space increased, we hypothesized that there would be a
proportional spreading of drug substance within the
interstitial space, as opposed to expansion, thus increas-
ing the surface area for lymphatic drainage. The volume
then attributed to the LDC was considered proportional
to the volume of the SC depot compartment. LDC vol-
ume was parameterized as a fraction of the SC depot
compartment, denoted as Vfrac and estimated by fitting
to the dose-normalized CPT data for all observed sub-
jects. For this procedure, the PBPK model for an average
human was coded into Phoenix NLME (v1.3, Certara)
and estimation of the population mean Vfrac and between
subject variability (as a log-normally distributed random
effect) was performed using the first-order conditional es-
timation with interaction algorithm (FOCE-ELS).
Estimation was performed by considering the actual
volume injected since the concentration varied across
the five dose cohorts where all remaining parameters
were fixed at the mean values previously optimized for a
virtual human (Offman and Edginton 2015). An add-
itional sensitivity analysis was performed whereby the
optimization of Vfrac was based solely on the CPT data
obtained for a single dose level in the human investiga-
tion. An objective function calculated as the absolute,
average deviation of the median predicted concentration
vs. median observed concentration at each nominal time
point for each study cohort was employed to discrimin-
ate between models with and without an LDC.
Model qualification
All simulations were performed using MATLAB®
(v2014b, Mathworks). Adequacy of the model in describ-
ing the study population was assessed following simula-
tion of 1000 virtual male subjects based on the study
population characteristics with body weight constrained
to the per protocol specified body weight (60–80 kg)
and normal GFR (90–150 mL/min). Histograms were
generated for height, weight and body mass index (BMI)
to verify the generated population was consistent with
the study population and included plausible individuals.
Sensitivity analysis
A sensitivity analysis was performed to evaluate the
model response to perturbation of the mean values of
the parameters deemed to be the most uncertain and to
evaluate the effect of incorporating or removing a distri-
bution on certain parameters where the distribution was
deemed uncertain. Mean parameter sensitivity was per-
formed for Vfrac, σsf, σi, NRCL, LS and FGFR. For each
perturbation, 100 individuals were simulated at the low-
est dose level (45 mg) and one parameter at a time was
perturbed by ±10 %, except σsf, which was perturbed
upwards of 1 % to avoid any single organ σv from ex-
ceeding 1. To evaluate sensitivity, non-compartmental
analysis was performed on the median (50th percentile)
simulated concentration vs. time profile to derive the
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AUC0-inf and Cmax. Change from the final model (with
LDC) as a percent was expressed and plotted graphically
by perturbation of the mean parameter value.
A sensitivity analysis on distributions was also per-
formed by simulating 1000 individuals and either per-
turbing or removing a parameter distribution one at a
time. The simulations for each scenario were plotted
and compared. This analysis was completed to define
the importance of specific parameter distributions on
overall CPT variability.
Results
One of the primary objectives of this investigation was
to develop a population generator with a lymphatic sys-
tem component. As a population generator, the model
produced a population consistent with the study popula-
tion (Fig. 2). With body height sampled from a normal
distribution and total BM truncated to a range of 60–
80 kg, the resultant BMIs fell largely within the typical
range normally included in Phase 1 healthy volunteer
research (18–28 kg/m2), with only a few of the 1000
simulated individuals falling outside this range. The
histogram for GFR, calculated as a product of the indi-
vidual FF and renal plasma flow verified that the final
population included only males with normal renal func-
tion within the specified range of 90–150 mL/min.
Using the mean virtual human model and the ob-
served dose-normalized data, Vfrac was estimated with
high precision (16.8 %) with a mean and interindividual
coefficient of variation of 0.25 (68 %). This value repre-
sents the volume of LDC expressed as a fraction of the
SC depot volume. Although sampled from a normal dis-
tribution, Vfrac for each individual was greater than zero
for simulated individuals due to the truncation and
constraining methods applied to the organ mass distri-
butions. A sensitivity analysis confirmed that similar
results were obtained regardless of whether Vfrac is
sampled from a normal distribution with constraints ver-
sus sampling from a log-normal distribution suggesting
the type of distribution does not influence the predictive
capacity of the model (Willmann, et al. 2007; McNally,
et al. 2014).
Fig. 2 Model output anthropometric distribution of weight (upper left panel), height (upper right panel), body mass index (lower left panel) and
derived glomerular filtration rate (lower right panel) for 1000 simulated individuals
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Figure 3, illustrates the comparison of the models
with and without LDC when simulated for a popula-
tion (n = 1000, 200/dose level). Visual inspection of the
log-log CPT (Fig. 3, right panel) illustrates an over-
prediction of the absorption phase when a LDC is not in-
corporated. Inclusion of LDC resulted in a reduction of
the objective function from 107.11 to 21.10, relative to the
model excluding LDC and improved the prediction of the
absorption phase, particularly in the first 10 h post-dose.
The model, with LDC, predicted the interindividual
variability in all phases of the CPT (i.e. absorption, peak
and elimination) with observed data points falling on ei-
ther side of the 50th percentile curve and a few individ-
ual observations falling outside the 5th–95th percentile
ribbon. The one exception being a subject in the initial
dose cohort (i.e. 45 mg dose) who clearly exhibited an
anomalous profile, likely due to improper injection tech-
nique, as repeat analysis by the bioanalytical laboratory
confirmed the measured concentration values.
Using the one-at-a-time sensitivity test for mean pa-
rameters demonstrated that in spite of a profound influ-
ence on the early portion of the time course for this
particular drug, the impact of parameter perturbation on
peak and overall exposure (i.e. Cmax and AUC) was
relatively small (Fig. 4). The largest effect in terms of %
change from the final model resulted from a -10 % per-
turbation of σsf on both Cmax and AUC. As described in
the methods section, an upward perturbation was con-
strained to 1 % to avoid any of the individual organ vas-
cular reflection coefficients from exceeding 1. Even so, a
1 % change in the mean vascular reflection coefficient
scaling factor resulted in a visually detectable change in
AUC and Cmax, confirming the model sensitivity to this
parameter. Unsurprisingly, perturbations in FGFR and
NRCL parameters, which influence renal and non-renal
clearance, resulted in the next largest percent change in
AUC, whilst having little influence on Cmax.
To illustrate the impact of varying parameter distribu-
tion assumptions on the three phases of the CPT, sce-
narios are presented on both linear and log scales
(Fig. 5). Of the parameters tested, applying a distribution
assumption to LS, the parameter defining skin lymphatic
flow as a fraction of skin blood flow, had the greatest in-
fluence on the interindividual variation in the absorption
phase (Fig. 5 panels 4 & 5). Whereas in the model devel-
opment, only a mean valuefor LS was assumed, coeffi-
cients of variation of 10 and 50 % were empirically
selected and the width of the 5th–95th percentile ribbon
expanded as the variability increased. In addition to LS,
variability assumptions for the Vfrac parameter also in-
fluenced the interindividual variability in the absorption
phase of the CPT. Halving and doubling the estimated
variability assumption from 68 to 34 % and 136 %, re-
spectively resulted in a corresponding narrowing and
widening of the simulated values supporting our hypoth-
esis that the variability assumption for this parameter is
important in the prediction an SC administered pegy-
lated macromolecule CPT (Fig. 5, panels 2 & 3). With
respect to the peak portion of the CPT, variation in LS
and blood volume appeared to be the most influential
parameters when the distributional assumption was per-
turbed. For blood volume, the perturbation scenario in-
cluded removing the variability in its entirety for this
parameter and simulating a population based only on
Fig. 3 Model simulated and observed plasma concentrations of a linear PEG-40 conjugated peptide versus time in humans on linear scale (left
panel) and log scale (right panel). Within each panel, the left set of profiles represents the model without a lymph transit compartment and right
side, with a lymph transit compartment incorporated. Closed geometric symbols represent unique individual subjects across 5 dose levels. Solid
lines and grey shaded ribbon represents the median and 5th–95th percentile simulated concentrations from respective models
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the mean blood volume value (Fig. 5, panel 8). This
change considerably narrowed the interindividual vari-
ability at the peak of the curve which leads to an impre-
cise prediction of Cmax, thus supporting the importance
of including the selected blood volume variability
employed in the final model. Adding distributional as-
sumptions to FGFR, which was assumed to be static for
the final model simulations at 0.1 % of GFR, resulted in
an obvious broadening of the interindividual variability
in the latter portion (i.e. elimination) of the CPT (Fig. 5,
Fig. 4 Mean parameter sensitivity perturbations vs. percent change in AUC (top left), Cmax (top right) and Tmax (bottom left) for the 50th percentile
following simulation of 100 subjects. Closed geometric symbols represent perturbations as indicated in the legend
Fig. 5 Median (dashed line) and 5th–95th percentile (shaded ribbon) following simulation of 1000 virtual individuals on linear scale (left panel)
and log scale (right panel). For sub-panels 1–11 in each panel, the following unique scenarios are presented: (1) Final model (2) 0.5-fold final
model CV % for Vfrac (3) 2-fold final model CV % for Vfrac (4): Addition of 10 % CV % on LS (5) Addition of 50 % CV % on LS (6) Addition of 10 %
CV % on σi (7) Addition of 50 % CV % on σi (8) Removing distribution on blood mass (9) Removing distribution on lymph mass (10) Removing
distribution on skin mass (11) Addition of a 20 % CV % on FGFR
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panel 11). Of the other parameters tested, none had ob-
vious visually detectable effects across the stages of the
concentration vs. time course.
Discussion
The compound employed in the current evaluation and
the base structural PBPK model were the same used in
our previous publication illustrating the utility of incorp-
orating a SC depot in the prediction of a human CPT
directly from a single non-human primate species
(Offman and Edginton 2015). The molecule’s biodistri-
butional properties were assumed to be largely attribut-
able to the pegylated moiety, which represents >96 % of
the molecular weight. The current in silico investigation
demonstrates the scale-up from monkeys directly to a
population of humans across a range of body sizes as
opposed to a virtual human (weighing 70 kg).
The major objectives of this evaluation were two-fold
and inter-related. The first being to develop a population
PBPK model which incorporates distributional assump-
tions for the lymphatic system which could potentially
be applied to large molecule PK predictions in a human
population. The drug independent aspects of the model,
being mechanistic in nature, can thus be applied to gen-
erating a population of individuals regardless of weight
and height range and thus can be used to estimate the
variability in a more diverse population than what was
studied in the current report.
Conversion of the model to a population model was
non-trivial as there is a paucity of literature to support
integrating lymphatic anthropometric variability into
PBPK models. Initially, we followed previous authors in
terms of the distribution type (i.e. normal vs. log-
normal) and, where possible, employed similar variability
estimates (Table 1) (Willmann, et al. 2007; McNally, et al.
2014). For some organ compartments however, either
there was no information to inform said distribution or
the variability appeared unusually high. It may seem
counterintuitive to employ normal distributions with re-
spect to organ sizes given the possibility of drawing im-
plausibly small or even negative values. However, to be
consistent with reported literature we elected to retain
distributions as previously reported. Instead we per-
formed an informal sensitivity analysis which concluded
no appreciable difference in the prediction interval
across the simulated dose cohorts regardless of whether
a distribution was log-normal or not. In our final model
we employed two tiers of safeguards to mitigate the risk
of drawing extreme outliers or negative values when the
distribution was set as normal, with the first being trun-
cation to the 95th percentile of the distribution and the
second, constraining the lower bound to one tenth the
mean value. Intuitively, where future data supports,
population simulations should consider log-normally
distributions to avoid the likelihood of negative or un-
characteristically low values being drawn from the
distribution.
Prior to truncation of GFR, values within the initial
population led to values interpreted as renally impaired
or unusually high. After a thorough investigation, we
confirmed that kidney perfusion and renal plasma flow
on a per gram of tissue basis were consistently within
the expected range and consequently the root cause was
attributed to a larger than likely coefficient of variation
for male kidney mass used as an input into the model
(McNally, et al. 2014; Willmann, et al. 2007; de la
Grandmaison, et al. 2001). As a further safeguard against
inflated variability in kidney mass, especially given the
importance of renal elimination to the drug in question,
the model was set to reject any virtual individuals with
GFRs less than 90 mL/min, due to being associated with
renal impairment, and above 150 mL/min range, which
normal healthy individuals rarely achieve, even when
normalized to 1.73 kg/m2 BSA (2002b). This exercise sug-
gests that reported values for kidney mass variability may
necessitate further evaluation to ensure kidney function is
appropriately simulated in the virtual population.
As described in the Methods section, we empirically
assumed that the variability in lymphatic system volume
would be equal to that of the variability in blood volume.
Although there is not specific data to inform this hy-
pothesis, lymphatic vessels represent a parallel circula-
tory system and thus an assumption of blood volume
based on individual size was deemed a reasonable
approach.
The second objective of this in silico investigation was
to explore the advantage of incorporating a LDC to better
represent local drainage from a SC depot space, to facili-
tate predictions of SC administered macromolecules.
Lymph collector vessels which run through the SC
space picking up macromolecules, are reported to not
reach the deep fascia until a node is reached, and from
the skin can follow an unpredictable course, draining to
multiple lymph nodes (Uren, et al. 2003). To address the
lymphatic drainage of the drug from the SC site of ad-
ministration by lymphatic capillaries, and to quantify the
volume and variability in vessel volume, we elected to
parameterize this compartment as a fraction of injection
volume. The rationale for this approach is predicated on
the assumptions that (1) there are multiple afferent ves-
sels draining the site and (2) the drainage volume would
increase as the volume of injection increases due to
spreading within the interstitial space (Porter, et al.
2001). Precedent for this position is based on compari-
sons of high pressure SC auto injector and manual SC
injection of recombinant human growth hormone,
where increased pressure from the auto injector resulted
in a higher and earlier CPT peak compared to a manual
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syringe, which was attributed to greater spread of
injected material in the SC space (Verhagen, et al. 1995).
Other PBPK models with injection depots have
employed varying assumptions for lymphatic drainage.
Gill et.al. parameterized the SC depot as a fixed volume
and lymph flow estimated from literature reports on
macromolecule disappearance from the SC site (Gill,
et al. 2015). It’s unclear why the authors, however,
elected to estimate lymph flow for each study rather
than rely on a standardized the lymph flow rate for skin.
Lymphatic flow is a physiologic process and expected to
be driven by anthropometric characteristics variability;
consequently, the methods outlined by Gill do not ap-
pear to readily lend themselves to population simula-
tions. Moreover, an assumption of a fixed volume being
attributed to the SC depot is not realistic as injection
volume varies from compound to compound, and study
to study based on drug physicochemical properties and
tolerability to the injected drug concentration. Tegenge
& Mitkus, in simulated intramuscular (IM) injections
of squalene-containing compounds, parameterized the
lymphatic drainage by taking the total lymph node volume
and applying the fraction of lymph nodes assumed to
drain directly from the IM depot space (Tegenge and
Mitkus 2015; Tegenge and Mitkus 2013). This approach,
however assumes the drainage occurs directly from injec-
tion site to a single node. However, patterns of lymphatic
drainage from the skin are reported to vary substantially
among individuals, even from the same area of the skin
(Uren, et al. 2003).
Our model attempts to characterize local drainage by
attributing a physical space representing the lymphatic
capillary vessels the drug would journey through from
the interstitial space to the lymph node, and is consid-
ered an additive volume to the lymphatic system as pa-
rameterized in the model proposed by Shah and Betts,
(2012). Although it is well established that lymphatic
vessels drain from the skin, to our knowledge, an experi-
mentally obtained value for this volume has not be de-
termined. Consequently, it is challenging to build a
purely mechanistic model describing this drainage. Gill
et. al. considered the disappearance of labeled IgG from
the SC space as a means of estimating the transit of drug
from the injection site to the vasculature, and others
have used estimation procedures to fit a transit time par-
ameter (Gill, et al. 2015; Shah and Betts 2012). However,
a time parameter is not entirely mechanistic and cannot
necessarily be relied upon for scaling up from preclinical
species to human.
In contrast, parameterizing the LDC volume as a frac-
tion of the injection volume represents an approach
which assigns an anatomical volume to drug transit from
the SC space to the lymph nodes relying on the skin
lymph flow as a mechanistic driver of said transit. As
this was the initial use of this methodology, no prior in-
formation was available to inform this value. Therefore
we used mathematical estimation to optimize the value
based on observed data obtained in the human popula-
tion. Evaluation of the dose vs. exposure data suggested
that the pharmacokinetic exposure was linear across the
doses tested (unpublished data). Therefore we elected to
perform the optimization based on all available observed
data. However, as an informal sensitivity measure, we re-
estimated Vfrac based on only a subset of the population
which resulted in an indiscernible difference in the pre-
dicted vs. observed data (data not shown).
In the current model, the volume of the LDC was as-
sumed to be dependent only on the injection volume,
and independent of compound size. However, logically,
spreading of drug particles within the SC space in theory
could be influenced by the drug’s physicochemical char-
acteristics such as fluid viscosity and inactive excipients.
Therefore, the utility of our methodology requires quali-
fication with compounds across a broad pharmacologic
class and molecular weight, among other characteristics,
to qualify this approach for more general use.
Another consideration in developing PBPK models for
PK predictions of macromolecules after SC administration
is the bioavailability after SC injection. Macromolecules
are reported to vary in terms of their SC bioavailability, in-
dependent of molecular weight (Wang, et al. 2008; Richter,
et al. 2012). The current compound was previously dem-
onstrated to exhibit a relatively high SC bioavailability in
primates at approximately 90 % (data not shown). Our
model was largely able to predict the exposure in humans
when scaled from primates, by assuming non-renal clear-
ance processes are proportional to the volume of the space
clearance occurs in. The predictive capacity of our model
requires additional work, testing broader group of macro-
molecules with a wide range of SC bioavailability, to be
confidently applied in an a priori setting for drugs with
unknown SC bioavailability.
Based strictly on a percent change in AUC and Cmax,
perturbation of the mean LDC does not appear as influ-
ential in terms of peak and overall exposure. In this sce-
nario where the half-life was on average greater than
200 h based on non-compartmental analysis (data not
shown), relying on the % change in AUC and Cmax is
misleading, as inclusion of an LDC clearly was necessary
to achieve the same profile shape as the observed data
and resulted in a considerably smaller objective function.
Inclusion of LDC only appears necessary to delay transit
from the SC depot site immediately after administration.
Following the initial transit through the lymphatics, drug
mass that is not renally eliminated, recirculates to the
organs. Drug mass that reaches the skin interstitial space
that is not cleared by non-renal processes represents a
relatively small proportion of the total circulating mass.
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Inclusion of a transit compartment draining from the
full skin interstitial volume, parameterized identically to
the drainage from the SC depot, consequently did not im-
pact the model prediction (data not shown), and following
the rule of parsimony, was excluded from the final model.
However, incorporating lymphatic transit from the entire
interstitial volume may have utility in other scenarios
where multiple SC injection sites are being tested.
Despite the uncertainty in the mean and variability
values included as input into the model for the lymph
node compartment, the model was largely insensitive to
the mean value of the lymph node. In contrast, the
model exhibited the greatest sensitivity to the mean
value for skin lymph flow likely as a consequence of the
route of administration being SC. This is consistent with
our previously developed model for predicting the mean
time course of the same drug in humans from primates
(Offman and Edginton 2015). We specifically observed a
distinctly slower skin lymph flow was required relative
to the current assumed range of 0.2–1 % of blood flow
to an organ (Swartz 2001). Lymph flow is inherently dif-
ficult to measure in humans and has been assumed to
scale from animal values. As a fraction of blood flow, it
may not be reasonable to assume lymph flow represents
a similar fraction of blood flow across all organs, and in
fact Baxter reported a wide range of organ lymph flow
values in the mouse, with skin lymph flow representing
the lowest rate as an absolute value across all organs re-
ported (Baxter, et al. 1994). Jones et. al. has stated that
in spite of the wide range of reported lymph flows, many
of the previously cited models fit the observed data well,
and that this raises a fundamental question regarding
model parameterization (Jones, et al. 2013). Jones goes
on to state that approximately 0.07 % of fluid entering
the interstitial space returns to the blood via the lymph
when considering net fluid recirculation. It is interesting
to note that in our previous work for the same com-
pound (Offman and Edginton 2015), the optimized skin
lymph flow was 0.1 %, very close to the 0.07 % of blood
flow suggested by Jones et. al. More importantly, these re-
sults reinforce the argument that models being developed
for IV administration cannot simply be applied to SC ad-
ministration without consideration of specific lymphatic
drainage from the SC depot site.
Assuming interindividual variability of skin lymph flow
resulted in a wider prediction ribbon in the absorption and
peak portions of the curve. The shape of the ribbon, par-
ticularly around Cmax, confirms the vital importance of
this parameter in models intended to simulate the SC pro-
file of a macromolecule and also further supports the pre-
viously stated position that skin lymph flow may represent
a smaller fraction of blood flow than previously assumed.
Further evaluation of model sensitivity suggested clear-
ance mechanisms are important for characterizing the
interindividual variability of this pegylated peptide in a
population. As previously stated, despite the large mo-
lecular mass, pegylated compounds can be renally elimi-
nated in primates and humans albeit slowly, at a rate of
approximately 0.1 % of GFR (Baumann, et al. 2014). As
renal clearance accounted for approximately one third of
total body clearance we were particularly interested in
whether changes in renal function would result in a
change in peak and overall exposure. Perturbation of
FGFR, which in the current model represents a fraction
of GFR, can be interpreted as a surrogate for a change
in renal function and the results of the sensitivity ana-
lysis suggested that changes in renal function precipitate
a change in AUC. Whether this percent change is suffi-
cient to warrant a change in the recommended dose
however, is a function of the drug’s safety profile and the
relationship of exposure to safety.
Conclusion
This is the first PBPK model incorporating lymphatic
system anthropometric interindividual variability for the
purposes of simulating macromolecule PK in a popula-
tion. As a population generator, this model is capable of
simulating a population of individuals across a wide
range of body weight and heights for use with other
compounds with lymphatic distribution and transport. A
novel proposal of incorporating an anatomical space
representing lymphatic drainage by lymphatic capillaries
appears critical in characterizing the early time course
following drug absorption and the consequence of ex-
cluding the compartment results in poor prediction of
the observed data in the early portion of the CPT. Vari-
ability in this lymph transit compartment and skin
lymph flow exhibit the greatest influence on model
prediction as it pertains to the absorption phase of
the CPT following SC administration, whereas blood
volume and renal clearance exhibit the largest appar-
ent effect on Cmax and elimination phases of the
curve, respectively.
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